Results of Scheme Meeting
Bionomics (BNOX) shareholders have approved the company's proposed re-domiciliation from Australia to the United States through a Scheme of Arrangement. Under this scheme, Neuphoria Therapeutics Inc., a Delaware , will become Bionomics' ultimate parent company. The shareholder vote showed strong support with 96% of votes cast in favor and 87% of shareholders present voting in favor.
The implementation remains subject to several conditions, including approval from the Supreme Court of New South Wales and maintenance of the independent expert's favorable conclusion. If all conditions are met, the implementation is expected around December 24, 2024, with Neuphoria shares beginning trading on Nasdaq under the symbol NEUP on or shortly after that date.
I soci di Bionomics (BNOX) hanno approvato la proposta dell'azienda di trasferire la propria sede legale dall'Australia agli Stati Uniti attraverso uno Schema di Accordo. In base a questo schema, Neuphoria Therapeutics Inc., una società del Delaware, diventerà la società madre di Bionomics. Il voto degli azionisti ha mostrato un forte sostegno con il 96% dei voti espressi a favore e l'87% degli azionisti presenti che hanno votato in favore.
L'attuazione rimane soggetta a diverse condizioni, tra cui l'approvazione della Corte Suprema del New South Wales e il mantenimento della conclusione favorevole dell'esperto indipendente. Se tutte le condizioni saranno soddisfatte, l'attuazione è prevista intorno al 24 dicembre 2024, con le azioni di Neuphoria che inizieranno a essere scambiate su Nasdaq con il simbolo NEUP da quella data o poco dopo.
Los accionistas de Bionomics (BNOX) han aprobado la propuesta de la empresa para trasladar su sede legal de Australia a Estados Unidos a través de un Esquema de Arreglo. En virtud de este esquema, Neuphoria Therapeutics Inc., una empresa de Delaware, se convertirá en la empresa matriz de Bionomics. La votación de los accionistas mostró un fuerte apoyo con el 96% de los votos emitidos a favor y el 87% de los accionistas presentes votando a favor.
La implementación sigue siendo sujeta a varias condiciones, incluida la aprobación de la Corte Suprema de Nueva Gales del Sur y el mantenimiento de la conclusión favorable del experto independiente. Si se cumplen todas las condiciones, se espera que la implementación ocurra alrededor del 24 de diciembre de 2024, con las acciones de Neuphoria comenzando a cotizar en Nasdaq bajo el símbolo NEUP en esa fecha o poco después.
바이오노믹스 (BNOX) 주주들이 호주에서 미국으로 법적 본사를 이전하는 회사의 제안을 승인했습니다. 이 과정에서 뉴포리아 테라퓨틱스 인크., 델라웨어에 위치한 회사,가 바이오노믹스의 최종 모회사가 됩니다. 주주 투표에서 96%의 찬성 투표와 87%의 참석 주주들이 찬성 투표를 한 강력한 지지가 나타났습니다.
이행은 뉴사우스웨일스 대법원의 승인과 독립 전문가의 유리한 결론 유지 등 여러 조건을 충족해야 합니다. 모든 조건이 충족되면, 이행은 2024년 12월 24일경에 이루어질 것으로 예상되며, 뉴포리아 주식은 그 날짜 전후로 NEUP라는 기호로 나스닥에서 거래를 시작할 것입니다.
Les actionnaires de Bionomics (BNOX) ont approuvé la proposition de l'entreprise de transférer son siège social d'Australie vers les États-Unis par le biais d'un Schéma d'Arrangement. Dans le cadre de ce schéma, Neuphoria Therapeutics Inc., basée dans le Delaware, deviendra la société mère de Bionomics. Le vote des actionnaires a montré un fort soutien avec 96% des voix exprimées en faveur et 87% des actionnaires présents votant en faveur.
La mise en œuvre est soumise à plusieurs conditions, notamment l'approbation de la Cour suprême de Nouvelle-Galles du Sud et le maintien de la conclusion favorable de l'expert indépendant. Si toutes les conditions sont remplies, la mise en œuvre est prévue aux alentours du 24 décembre 2024, avec le début des échanges des actions de Neuphoria sur le Nasdaq sous le symbole NEUP à cette date ou peu après.
Die Aktionäre von Bionomics (BNOX) haben dem vorgeschlagenen Umzug des Unternehmens von Australien in die Vereinigten Staaten durch ein Schemas für Arrangements zugestimmt. Nach diesem Schema wird Neuphoria Therapeutics Inc., eine Gesellschaft aus Delaware, die Muttergesellschaft von Bionomics. Die Abstimmung der Aktionäre zeigte starke Unterstützung mit 96% der abgegebenen Stimmen dafür und 87% der anwesenden Aktionäre, die dafür gestimmt haben.
Die Umsetzung unterliegt mehreren Bedingungen, darunter die Genehmigung des Obersten Gerichtshofs von New South Wales und die Aufrechterhaltung der günstigen Schlussfolgerung des unabhängigen Experten. Wenn alle Bedingungen erfüllt sind, wird mit der Umsetzung um den 24. Dezember 2024 gerechnet, wobei die Aktien von Neuphoria an diesem Datum oder kurz danach unter dem Symbol NEUP an der Nasdaq gehandelt werden.
- Strong shareholder approval with 96% votes in favor
- Planned listing on Nasdaq under new ticker NEUP
- Maintains access to US capital markets through re-domiciliation
- None.
Insights
The overwhelming shareholder approval for Bionomics' re-domiciliation from Australia to the U.S. marks a significant corporate restructuring. With
The remaining conditions, including Supreme Court approval and independent expert confirmation, are primarily procedural. The anticipated December 24 implementation and subsequent NASDAQ listing under 'NEUP' symbol represents a material change in the company's corporate structure. This move typically signals improved access to U.S. capital markets and institutional investors, potentially benefiting the company's future funding capabilities.
The re-domiciliation to the U.S. is a strategic move that could significantly enhance Bionomics' market position and valuation potential. U.S.-domiciled biotechnology companies often command higher valuations compared to their Australian counterparts due to greater market liquidity, analyst coverage and institutional investor access. The strong shareholder support suggests investors recognize these potential benefits.
The transition to trade under NEUP could attract increased attention from U.S. biotech investors and potentially improve trading volumes. This corporate restructuring may also facilitate easier access to U.S. capital markets for future fundraising needs, which is important for biotechnology companies in development stages. The timing of the implementation before year-end could position the company for a fresh start in 2025.
ADELAIDE, Australia and CAMBRIDGE, Mass., Dec. 12, 2024 (GLOBE NEWSWIRE) -- Bionomics Limited (Nasdaq: BNOX) (“Bionomics” or the “Company”) is pleased to provide the following update on the status of its proposed re-domiciliation from Australia to the United States.
Bionomics shareholders have today approved, by the requisite majority, the proposed Scheme of Arrangement in relation to the Company’s proposed re-domiciliation from Australia to the United States, under which Neuphoria Therapeutics Inc., a Delaware corporation (“Neuphoria”), will become the ultimate parent company of Bionomics Limited following the implementation of the Scheme of Arrangement.
Voting Results
In summary:
96% of the votes cast by Bionomics shareholders were in favor of the Scheme; and87% of Bionomics shareholders present and voting (in person or by proxy, attorney or corporate representative) voted in favor of the Scheme.
Next Steps
Although Bionomics shareholder approval has been obtained, the Scheme remains subject to several customary conditions detailed in the Scheme Implementation Agreement, as amended and restated, between Bionomics and Neuphoria, including:
- the Supreme Court of New South Wales, Australia approving the Scheme at a hearing currently scheduled to occur at 3:00pm (Sydney time) on December 16, 2024 (“Second Court Hearing”);
- the independent expert not withdrawing or adversely modifying its conclusion that the Scheme is in the best interest of Bionomics shareholders; and
- the satisfaction or waiver of any remaining conditions prior to the Second Court Hearing.
Subject to these remaining conditions being satisfied or waived, implementation of the Scheme is expected to occur on or about December 24, 2024 and shares of Neuphoria are expected to begin trading on Nasdaq under the symbol “NEUP” on that date or as soon as possible thereafter.
For further information, please contact:
| General Rajeev Chandra Company Secretary CoSec@bionomics.com.au | Investor Relations Kevin Gardner kgardner@lifesciadvisors.com | Investor Relations Chris Calabrese ccalabrese@lifesciadvisors.com |
About Bionomics Limited
Bionomics (NASDAQ: BNOX) is a clinical-stage biotechnology company developing novel, potential first-in-class, allosteric ion channel modulators to treat patients suffering from serious central nervous system (“CNS”) disorders with high unmet medical need. Bionomics is advancing its lead drug candidate, BNC210, an oral, proprietary, selective negative allosteric modulator of the α7 nicotinic acetylcholine receptor, for the acute treatment of Social Anxiety Disorder (SAD) and chronic treatment of Post-Traumatic Stress Disorder (PTSD). Beyond BNC210, Bionomics has a strategic partnership with Merck & Co., Inc. (known as MSD outside the United States and Canada) with two drugs in early-stage clinical trials for the treatment of cognitive deficits in Alzheimer’s disease and other central nervous system conditions. Bionomics’ pipeline also includes preclinical assets that target Kv3.1/3.2 and Nav1.7/1.8 ion channels being developed for CNS conditions of high unmet need.
Forward-Looking Statements
Bionomics cautions that statements included in this press release that are not a description of historical facts are forward-looking statements. Words such as “may,” “could,” “will,” “would,” “should,” “expect,” “plan,” “anticipate,” “believe,” “estimate,” “intend,” “predict,” “seek,” “contemplate,” “potential,” “continue” or “project” or the negative of these terms or other comparable terminology are intended to identify forward-looking statements. The forward-looking statements are based on our current beliefs and expectations. The inclusion of forward-looking statements should not be regarded as a representation by Bionomics that any of its plans will be achieved. Actual results may differ materially from those set forth in this release due to the risks and uncertainties inherent in the Company’s business and other risks described in the Company’s filings with the SEC, including the Company’s Annual Report on Form 10-K filed with the SEC, and its other reports. Investors are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof, and Bionomics undertakes no obligation to revise or update this news release to reflect events or circumstances after the date hereof. Further information regarding these and other risks, uncertainties and other factors is included in Bionomics’ filings with the SEC, copies of which are available from the SEC’s website (www.sec.gov) and on Bionomics’ website (www.bionomics.com.au) under the heading “Investor Center.” All forward-looking statements are qualified in their entirety by this cautionary statement. This caution is made under the safe harbor provisions of Section 21E of the Private Securities Litigation Reform Act of 1995. Bionomics expressly disclaims all liability in respect to actions taken or not taken based on any or all the contents of this press release.
Not an offer of securities
This press release does not constitute an offer to sell, or the solicitation of an offer to buy, any securities in any jurisdiction. The Neuphoria shares have not been registered under the U.S. Securities Act of 1933 and may not be offered or sold except in a transaction registered under the Securities Act or in a transaction exempt from, or not subject to, such registration requirements and applicable U.S. state securities laws.
FAQ
When will Bionomics (BNOX) complete its re-domiciliation to the US?
What percentage of Bionomics shareholders voted in favor of the re-domiciliation scheme?
What will be Neuphoria Therapeutics' new stock symbol after the BNOX re-domiciliation?
What conditions remain for the Bionomics (BNOX) re-domiciliation to complete?
